Rubraca Maintenance Approved in Europe for Relapsed Ovarian Cancer

Rubraca Maintenance Approved in Europe for Relapsed Ovarian Cancer
The European Commission has extended Rubraca's (rucaparib) approval as a maintenance therapy for women with advanced, relapsed ovarian cancer who are in complete or partial response to platinum-based chemotherapy. This recent approval — which makes Rubraca available to all women regardless of their BRCA mutational status — is an extension of a marketing authorization granted in May 2018 for women with BRCA-mutated ovarian cancer. It covers patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. “This EC authorization of rucaparib is an important step in ensuring that it is available to all women who may potentially benefit, regardless of their BRCA status,” Patrick J. Mahaffy, president and CEO of Clovis Oncology, said in a press release. Rubraca is a kind of treatment called a PARP inhibitor. PARP enzymes are key in repairing damage to the cell’s DNA, meaning their activity in cancer cells allows them to survive. PARP inhibitors prevent the enzymes from doing their job, leading to the accumulation of DNA damage, and ultimately triggering the death of these cancer cells. The European Commission's decision was based on data from the Phase 3 ARIEL3 trial (NCT01968213), where Rubraca maintenance extended the time patients lived without disease progr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *